Clinical research organisation (CRO) Open Orphan has announced that its subsidiary hVIVO has signed a contract with AIM ImmunoTech to test its antiviral candidate, Ampligen, against the human Rhinovirus HRV, or common cold, and influenza, in a single human challenge study model.
AIM ImmunoTech, a biopharmaceutical company, will sponsor the Phase 2 human challenge trial, which will be conducted by hVIVO. The study is expected to start towards the end of 2021 and hVIVO is looking at signing more contracts in the area of respiratory and infectious diseases following the outbreak of Covid-19.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).